SCHEMBL4289694

SCHEMBL4289694

COCCOc1cc(N)ccc1C(=O)Nc1nccs1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.56
NPC1 O15118 6/20 0.56
MAPT P10636 2/20 0.56
POLB P06746 1/20 0.56
MAPK1 P28482 2/20 0.55
ALOX15 P16050 1/20 0.55
HSD17B10 Q99714 1/20 0.54
ADORA2A P29274 1/20 0.53
ADORA1 P30542 1/20 0.53
SMN1; SMN2 Q16637 5/20 0.53
LMNA P02545 1/20 0.53
RECQL P46063 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
KCNMA1 Q12791 1/20 0.53
ALDH1A1 P00352 2/20 0.51
GAA P10253 1/20 0.51
GCK P35557 1/20 0.50
AGER Q15109 1/20 0.49
TSHR P16473 1/20 0.49
MEN1 O00255 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4288720 0.91 MAPK1 (0.58) RAB9ANPC1MAPTPOLBMAPK1
SCHEMBL4286251 0.88 RAB9A (0.71) RAB9ANPC1MAPTPOLBMAPK1
SCHEMBL4288727 0.80 ADORA2A (0.62) RAB9ANPC1MAPTPOLBMAPK1
SCHEMBL4293175 0.80 ADORA2A (0.83) RAB9ANPC1MAPTPOLBMAPK1
SCHEMBL4286249 0.80 RAB9A (0.65) RAB9ANPC1MAPTPOLBMAPK1
SCHEMBL4295738 0.79 NPC1 (0.66) RAB9ANPC1MAPTPOLBHSD17B10
SCHEMBL16073069 0.77 RAB9A (0.72) RAB9ANPC1MAPTPOLBMAPK1
SCHEMBL4293147 0.77 ADORA2A (0.58) RAB9ANPC1MAPTPOLBMAPK1
SCHEMBL27643462 0.77 GCK (0.64) RAB9ANPC1ADORA2ASMN1; SMN2LMNA
SCHEMBL4293361 0.77 NPC1 (0.62) RAB9ANPC1SMN1; SMN2LMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US disclosed
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP disclosed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP disclosed
EP-1682129-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-07-26 EP disclosed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US disclosed
WO-2005039572-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES ADORA2A, ADORA3, ADORA1 RAB9A 2380/4885NPC1 1022/4885MAPT 1300/4885
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives ADORA2A, ADORA3, ADORA1 RAB9A 2380/4885NPC1 1022/4885MAPT 1300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.